PCV

Vaxcyte Reports Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 7, 2022
Investment, Fast track (FDA), Ageing, Immunoglobulin G, Growth, SEC, Company, Periodontal disease, Private Securities Litigation Reform Act, Expected, Program, Infection, Regulation of tobacco by the U.S. Food and Drug Administration, Peterborough, U.S. Securities and Exchange Commission, General Administration of Sport of China, Antigen, SAN, Sutro Biopharma, G&A, Immunization, Disease, Meningitis, Exercise, GLOBE, IND, IPD, FDA, Vaccine, Chemistry, Fast Track, Population, Administration, PCV, Genetically modified bacteria, Vaccination, Tolerability, R, Safety, Adult, OPA, Food, Review, Key, Research and development, VAX, Success, Infant, Security (finance), Pharmaceutical industry, Clothing, Generic drug, COVID-19

SAN CARLOS, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the third quarter ended September 30, 2022 and provided a business update.

Key Points: 
  • We believe these results support a best-in-class potential for VAX-24 and present an opportunity to set a new bar for immunogenicity standards for pneumococcal vaccines.
  • The aggregate net proceeds to Vaxcyte from this offering were approximately$650.7 million after deducting underwriting discounts and commissions and other offering expenses payable by Vaxcyte.
  • VAX-PG: Vaxcyte expects to nominate a final vaccine candidate for VAX-PG, its novel therapeutic vaccine designed to treat periodontal disease, by the end of 2022.
  • Vaxcyte undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

Vaxcyte to Present at Upcoming Investor Conferences

Retrieved on: 
Thursday, November 3, 2022
Company, SAN, GLOBE, Investor, Webcast, Infection, Periodontal disease, Fireside chats, PCV, Genetically modified bacteria, Vaccine, Sutro Biopharma, Antigen, Wood drying

A replay of each webcast will be available for approximately 30 days following the conference.

Key Points: 
  • A replay of each webcast will be available for approximately 30 days following the conference.
  • Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases.
  • Vaxcytes lead candidate, VAX-24, is a 24-valent, broad-spectrum, carrier-sparing pneumococcal conjugate vaccine being developed for the prevention of invasive pneumococcal disease.
  • Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.

Vaxcyte Announces Closing of $690 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Friday, October 28, 2022
808, Bank of America, State Street, SEC, Company, Security (finance), U.S. Securities and Exchange Commission, Guggenheim Partners, BofA Securities, Madison Avenue, Prospectus, Sutro Biopharma, Jefferies, Vaccine, 3rd Floor, PCV, Floor, Jefferies Group, Antigen, GLOBE, LLC, Needham & Company, Infection, Attention, Genetically modified bacteria, Equity capital markets, Telephone, SAN, Periodontal disease, Guggenheim, Sale, Exercise

This includes the exercise in full by the underwriters of their option to purchase up to 2,812,500additional shares of common stock at the public offering price per share, less underwriting discounts and commissions.

Key Points: 
  • This includes the exercise in full by the underwriters of their option to purchase up to 2,812,500additional shares of common stock at the public offering price per share, less underwriting discounts and commissions.
  • The aggregate gross proceeds to Vaxcyte from this offering were approximately$690.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Vaxcyte.
  • BofA Securities, Jefferies, SVB Securities, Evercore ISI and Guggenheim Securities acted as joint book-running managers for the offering.
  • Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.

Vaxcyte Announces Pricing of $600 Million Public Offering

Retrieved on: 
Wednesday, October 26, 2022
808, Bank of America, State Street, SEC, Company, Security (finance), U.S. Securities and Exchange Commission, Guggenheim Partners, BofA Securities, Madison Avenue, Prospectus, Sutro Biopharma, Jefferies, Vaccine, 3rd Floor, PCV, Floor, Jefferies Group, Antigen, GLOBE, Cantor, Needham & Company, Infection, LLC, Attention, Genetically modified bacteria, Equity capital markets, Telephone, SAN, Periodontal disease, Guggenheim, Sale, Exercise

Vaxcyte is selling 15,000,000 shares of common stock and pre-funded warrants to purchase 3,750,000 shares of common stock in the offering.

Key Points: 
  • Vaxcyte is selling 15,000,000 shares of common stock and pre-funded warrants to purchase 3,750,000 shares of common stock in the offering.
  • The shares of common stock are being sold at a public offering price of $32.00 per share, and the pre-funded warrants are being sold at a public offering price of $31.999 per underlying share.
  • The aggregate gross proceeds to Vaxcyte from this offering are expected to be approximately $600.0 million, before deducting underwriting discounts and commissions and other offering expenses, and excluding the exercise of any pre-funded warrants.
  • All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte.

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

Retrieved on: 
Monday, October 24, 2022
808, SAN, Sutro Biopharma, Floor, U.S. Securities and Exchange Commission, Equity capital markets, Sale, Telephone, SEC, Vaccine, Infection, LLC, Jefferies Group, Madison Avenue, Security (finance), Periodontal disease, Attention, Bank of America, Company, BofA Securities, Needham & Company, State Street, Guggenheim Partners, Cantor, GLOBE, Genetically modified bacteria, Prospectus, Jefferies, Antigen, 3rd Floor, PCV, Guggenheim

All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte.

Key Points: 
  • All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte.
  • Vaxcyte intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of its common stock offered in the public offering (including shares underlying the pre-funded warrants).
  • BofA Securities, Jefferies, SVB Securities, Evercore ISI and Guggenheim Securities are acting as joint book-running managers for the offering.
  • Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.

Vaxcyte Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64

Retrieved on: 
Monday, October 24, 2022
SAN, Streptococcus pneumoniae, Conference, IND, Infection, Infant, Private Securities Litigation Reform Act, Investigational New Drug, Program, Mortality, Meningitis, 20B, Sinusitis, Chemistry, Bacteria, Subclinical infection, Streptococcus, Antigen, Immunoglobulin G, Pneumonia, Immunization, Company, 23F, GLOBE, Genetically modified bacteria, FDA, Sutro Biopharma, PD, Review, Vaccine, OPA, Security (finance), Ageing, U.S. Securities and Exchange Commission, Vaccination, PCV, Host, Immunodeficiency, Otitis media, Disease, Peterborough, SEC, Webcast, Periodontal disease, IPD, VAX, Adult, Safety, Fast Track, 10A, Death, Public health, Pharmaceutical industry, Generic drug, COVID-19

-- Vaxcyte to Advance Potential Best-in-Class VAX-24 Clinical Program in Adult and Pediatric Populations --

Key Points: 
  • These four incremental serotypes cover 10-15 percent of strains causing invasive pneumococcal disease (IPD) over the current standard-of-care in adults.
  • We are thrilled with these positive topline results from our Phase 1/2 proof-of-concept study, which met all of our objectives.
  • The study results demonstrate that VAX-24 has the potential to provide broader coverage and better immune responses relative to the standard-of-care.
  • Topline safety, tolerability and immunogenicity data from the infant Phase 2 study primary 3-dose immunization series are expected by 2025.

Vaxcyte to Host Webcast and Conference Call to Discuss Topline Results from the Phase 1/2 Proof-of-Concept Study of VAX-24 Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults

Retrieved on: 
Sunday, October 23, 2022
SAN, Sutro Biopharma, U.S. Securities and Exchange Commission, SEC, Webcast, Vaccine, Infection, Private Securities Litigation Reform Act, Security (finance), Periodontal disease, Company, Ageing, Safety, Chemistry, GLOBE, Genetically modified bacteria, PCV, Antigen, COVID-19

Those who would like to participate may access the live webcast here , or register in advance for the teleconference here .

Key Points: 
  • Those who would like to participate may access the live webcast here , or register in advance for the teleconference here .
  • A live webcast of the conference call will also be available on the investor relations page of theVaxcyte corporate website at www.vaxcyte.com .
  • After the live webcast, the event will remain archived on theVaxcyte website for 30 days.
  • Vaxcytes lead candidate, VAX-24, is a 24-valent, broad-spectrum pneumococcal conjugate vaccine being developed for the prevention of invasive pneumococcal disease.

Vaxcyte Expands Executive Leadership Team with Key Appointments

Retrieved on: 
Tuesday, October 11, 2022
SAN, Hepatitis A, Drug, Infection, Private Securities Litigation Reform Act, Licensure, Corporation, University, National, Chemistry, Antigen, Rituximab, Pfizer, Vaccine, Johnson & Johnson, TRACON, Genentech, Executive, Company, Marketing, GLOBE, Genetically modified bacteria, Harbor–UCLA Medical Center, History of the University of Maryland, College Park, Sutro Biopharma, Shigella, Biogen, University of Maryland Center for Environmental Science, Security (finance), U.S. Securities and Exchange Commission, PCV, Syracuse University, Ebola, Measles, SEC, Business, Periodontal disease, Schering-Plough, Business development, Public health, Management, Pharmaceutical industry, Merck, Medicine, Growth, COVID-19, Epidemiology

SAN CARLOS, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the appointment of Mark Wiggins as Chief Business Officer and Jakub Simon as Chief Medical Officer. Both Mark and Jakub are accomplished industry leaders who bring vast expertise that will support the continued growth and advancement of the Company.

Key Points: 
  • Vaxcyte is poised for substantial growth with a potential global PCV vaccine franchise, said Mark Wiggins, Chief Business Officer of Vaxcyte.
  • Im thrilled to be joining the Company at this stage and to be part of a dedicated, forward-thinking team on a mission to advance such important vaccines.
  • I am pleased to join this team driven by a bold mission grounded in addressing significant public health challenges with respect to bacterial infectious diseases and antibiotic resistance, said Jakub Simon, Chief Medical Officer of Vaxcyte.
  • Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.

Global Pneumococcal Vaccine Market Report 2022: Escalating Birth Rates & Rising Parental Concerns Fuel Sector - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 27, 2022
Health, Pharmaceutical, Health, COVID-19, Risk, PCV, Infant, World, World Health Organization, Smoker, Immunization, Streptococcus, WHO, Parent, Streptococcus pneumoniae, Disease, CAGR, Vaccine, Growth

The "Pneumococcal Vaccine Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pneumococcal Vaccine Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global pneumococcal vaccine market size reached US$ 8.5 Billion in 2021.
  • Looking forward, the publisher expects the market to reach US$ 11.6 Billion by 2027, exhibiting a CAGR of 5.32% during 2021-2027.
  • Moreover, the introduction of the Pneumococcal Conjugate Vaccine (PCV) in infant routine immunization by governing agencies of numerous countries is anticipated to propel the market growth.

Global Pneumococcal Vaccines Market Report (2022 to 2027) - Growing Incidence of Childhood Pneumonia is Driving the Industry - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 27, 2022
Health, Pharmaceutical, Streptococcus, Incidence, Child, UNDP, COVID-19, PCV, FDA, UNICEF, Disease, Food, Central African, Vaccination, Immunization, GSK, Growth, Conjugate vaccine, Government, Regulation of tobacco by the U.S. Food and Drug Administration, Serum Institute of India, Serum, Pneumonia, Vaccine, AstraZeneca, PATH, Inactivated vaccine, WHO, Infection, Streptococcus pneumoniae, Fatality, Bill & Melinda Gates Foundation, Awareness, Mortality, Merck, Pfizer, Death, Pharmaceutical industry

Vaccines that help prevent pneumococcal disease caused by Streptococcus pneumoniae bacteria are classified as pneumococcal vaccines.

Key Points: 
  • Vaccines that help prevent pneumococcal disease caused by Streptococcus pneumoniae bacteria are classified as pneumococcal vaccines.
  • Pneumococcal diseases are most common in younger children; however, adults and the elderly are more prone to pneumococcal contaminations and even death.
  • Pneumonia vaccines are primarily given to children under two years and adults 65 years and older.
  • The market leaders for the Global Pneumococcal Vaccines Market are Pfizer, GSK, Merck Serum Institute of India Pvt Ltd, and AstraZeneca.